822O Activation of γ9δ2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed/refractory hematologic cancers (EVICTION trial) von Garciaz, S., Champiat, S., Peterlin, P., Lemmens, K., de Gassart, A., Brune, P., Valentin, E., Leparquier, C., Iche, M., Olive, D., Vey, N., Frohna, P.A.

Volltext

732MO The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma... von Champiat, S., Wermke, M., Vicier, C., de Bono, J.S., Jungels, C., Vey, N., Kotecki, N., Wetzko, K., Ruhnke, L., Garralda, E., Galvao de Aguiar, V., Lorusso, P., de Gassart, A., Valentin, E., Brune, P., Iche, M., Leparquier, C., Olive, D., Marabelle, A., Frohna, P.A.

Volltext

Ready to use product e.g. salad, conditioning method, involves placing products in package, introducing conditioning gas in package, and sealing package with polypropylene or polyp... von LEPARQUIER BERTRAND

Volltext bestellen